|
|
|
| Effects of Sacubitril and Valsartan Sodium Tablets on ventricular remodeling in patients with heart failure complicated with hyponatremia#br# |
| GAO Ke YANG Jun XU Huajian▲ |
| Department of Cardiovascular Internal Medicine, Huai’an First People’s Hospital Branch, Jiangsu Province, Huaian 223002, China |
|
|
|
Abstract Objective To investigate the effects of Sacubitril and Valsartan Sodium Tablets on ventricular remodeling in patients with heart failure complicated with hyponatremia. Methods A total of 82 patients with heart failure complicated with hyponatremia who were diagnosed and treated in Huai’an First People’s Hospital Branch from March 2017 to March 2020 were selected and divided into study group and control group by random number table method, with 41 cases in each group. The control group was given Tolvaptan Tablets, while the study group was given Tolvaptan Tablets, Sacubitril and Valsartan Sodium Tablets. The therapeutic effect and drug safety of the two groups were compared. Results The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). After treatment, left ventricular ejection fraction (LVEF) in two groups was higher than before treatment, left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). After treatment, the LVEDD and LVESD in the study group were lower than those in the control group, while the LVEF was higher than that in the control group, with statistically significant differences (P ＜ 0.05). After treatment, serum sodium in the two groups was higher than before treatment, and N-terminal brain natriuretic peptide precursor (NTpro-BNP) and interleukin-33 (IL-33) were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). After treatment, the sodium content in the study group was higher than that in the control group, while the levels of NTpro-BNP and IL-33 in the study group were lower than those in the control group, and the differences were statistically significant (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Sacubitril and Valsartan Sodium Tablets in the treatment of heart failure complicated with hyponatremia can inhibit ventricular remodeling, improve the levels of hyponatremia, inflammatory factors, and neuroendocrine factors, thereby enhancing the therapeutic efficacy, with good safety.
|
|
|
|
|
|
[1] Solomon SD，McMurray JJV，Anand IS，et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction [J]. N Engl J Med，2019，381（17）：1609-1620.
[2] Armstrong PW，Pieske B，Anstrom KJ，et al. Vericiguat in patients with heart failure and reduced fjection fraction [J]. N Engl J Med，2020，382（20）：1883-1893.
[3] Tromp J，Teng TH，Tay WT，et al. Heart failure with preserved ejection fraction in Asia [J]. Eur J Heart Fail，2019，21（1）：23-36.
[4] Sterns RH. Treatment of severe hyponatremia [J]. Clin J Am Soc Nephrol，2018，13（4）：641-649.
[5] 中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.急性心力衰竭基层诊疗指南（实践版2019）[J]. 中华全科医师杂志，2019，18（10）：931-935.
[6] 肖幸，李珊珊，凃玲，等.托伐普坦治疗老年心力衰竭的回顾性研究[J].中国医院药学杂志，2019，39（18）：66-68.
[7] 郑焱，郑芬萍，李红.住院患者低钠血症的患病率和病因分析[J].中华内科杂志，2020，59（1）：29-34.
[8] Kiuchi S，Ikeda T. Hemodynamic and hormonal effects of tolvaptan for heart failure [J]. Intern Med，2019，58（4）：471-475.
[9] Sekine A，Hoshino J，Fujimaru T，et al. Genetics may predict effectiveness of tolvaptan in autosomal dominant polycystic kidney disease [J]. Am J Nephrol，2020，51（9）：745-751.
[10] 董萌.沙库巴曲缬沙坦钠治疗老年慢性心力衰竭合并肾功能不全患者的临床观察[J].中国中西医结合急救杂志，2020，27（1）：84-87.
[11] 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志，2018，2（4）：196-225.
[12] Rodriguez M，Hernandez M，Cheungpasitporn W，et al. Hyponatremia in heart failure：pathogenesis and management [J]. Curr Cardiol Rev，2019，15（4）：252-261.
[13] 成翠红.米力农联合托伐布坦治疗老年心力衰竭伴低钠血症疗效研究[J].中国药物与临床，2019，19（5）：119-120.
[14] 金曼，张洁，殷令妮，等.托伐普坦联合高渗盐水对心力衰竭合并低钠血症患者心功能及血浆B型利钠肽的影响[J].检验医学与临床，2020，17（12）：119-121.
[15] 张帆，杨文慧，何燕，等.心力衰竭患者合并低钠血症预后研究进展[J].心血管病学进展，2018，39（2）：87-90.
[16] Patorno E，Pawar A，Franklin JM，et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care [J]. Circulation，2019，139（25）：2822-2830.
[17] Cox ZL，Hung R，Lenihan DJ，et al. Diuretic strategies for loop diuretic resistance in acute heart failure：The 3T trial [J]. JACC Heart Fail，2020，8（3）：157-168.
[18] 吴晓光，王丽，张桐艳.托伐普坦在老年心力衰竭低钠血症患者中应用[J].临床军医杂志，2019，47（2）：213-214.
[19] 张金月，刘启凤，杨柳，等.心力衰竭研究的组学视角[J].药学学报，2020，55（5）：78-88.
[20] 张德龙，殷莉，姜芳，等.心舒宁汤联合曲美他嗪治疗尿毒症性心肌病疗效及对N末端脑钠肽前体和心脏腔室的影响[J].现代中西医结合杂志，2019，28（11）：1181-1184.
[21] 王毅，杨征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志，2019，48（4）：64-66.
[22] McCarthy PC，Phair IR，Greger C，et al. IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2/3 [J]. Immunol Cell Biol，2019，97（1）：54-71.
[23] 赵小龙，陈文亮.IL-33/ST2信号通路在急性胰腺炎及纤维化中的作用[J].中国现代普通外科进展，2019，22（2）：43-47.
[24] 宋丽颖，袁慧.可溶性ST2在心血管相关疾病排除诊断和治疗监测的应用前景[J].中华检验医学杂志，2020， 43（3）：239-244.
[25] 张相杰，黄文平，许有凡.沙库巴曲缬沙坦和盐酸贝那普利片对心力衰竭患者心室重塑，炎症因子的影响[J].实用医学杂志，2019，35（5）：125-129. |
|
|
|
